Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Phase 2 Completed 34 enrolled University of California, Irvine Exelixis · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.

Timeline

Start: 2020-02-04
Primary completion: 2023-11-25
Completion: 2025-09-16

Outcome

Met primary endpoint

paper The primary endpoint was met. PMID 38823034 ↗

Publications

Dayyani F, Chao J, Lee FC, Taylor TH, Neumann K, Cho MT. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors. Oncologist. 2024 Aug 5;29(8):721-e1088. doi: 10.1093/oncolo/oyae117.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cabozantinib	Small molecule	40 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous